Immunology of HIV - Filling in the details

International Journal of STD and AIDS

Volumn 15, Issue 9, 2004, Pages 574-583

  Buckland, Matthew S ^a   Pinching, A J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; AUTOANTIBODY; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PNEUMOCOCCUS VACCINE; POLYCLONAL ANTIBODY; ZIDOVUDINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; GENE DELETION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NATURAL KILLER CELL; NEUTROPENIA; NEUTROPHIL; PATIENT MONITORING; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TH2 CELL; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY;

EID: 4644245912     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462041724217     Document Type: Review

References (115)

1. Riera A, Gimferrer E, Cadafalch J, Remacha A, Martin S. Prevalence of high serum and red cell ferritin levels in HIV-infected patients. Haematohgica 1994;79:165-7
2. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002;99:7015-20
3. Moore DA, Sullivan A, Hilstead P, Gazzard BG. A retrospective study of neutropenia in HIV disease. Int J STD AIDS 2000;11:8-14
4. Murphy MF, Metcalfe P, Waters AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 1987;66:337-40
5. Tumbarello M, Tacconelli E, Donati KG, et al. HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr 2000;23:145-51
6. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998,12:65-74
7. Kerst JM, de Haas M, van der Schoot CE, et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 1993;82:3265-72
8. Kuijpers TW, de Haas M, de Groot CJ, dem Borne AE, Weening RS. The use of rhG-CSF in chronic autoimmune neutropenia: reversal of autoimmune phenomena, a case history. Br J Haematol 1996;94:464-9
9. Bux J, Kissel K, Nowak K, Spengel U, Mueller-Eckhardt C. Autoimmune neutropenia: clinical and laboratory studies in 143 patients. Ann Hematol 1991;63:249-52
10. Rubinstein DB, Farrington GK, O'Donnell C, Hartman KR, Wright DG. Autoantibodies to leukocyte alphaMbeta2 integrin glycoproteins in HIV infection. Clin Immunol 1999;90:352-9
11. Rolston KV, Radentz S, Rodriguez S. Bacterial and fungal infections in patients with the acquired immunodeficiency syndrome. Cancer Detect Prev 1990;14:377-81
12. Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol 1994;55:341-80
13. Ljunggren HG, Karre K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol Today 1990;11:237-44
14. Ruggeri L, Capanni M, Martelli MF, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr Opin Hematol 2001;8:355-9
15. Sirianni MC, Vincenzi L, Topino S, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002;32:2711-20
16. Lebbe C, de Cremoux P, Millot G, et al. Characterization of in vitro culture of HIV-negative Kaposi's sarcoma-derived cells. In vitro responses to alfa Interferon. Arch Dermatol Res 1997;289:421-8
17. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002;22:295-303
18. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000;343:37-49
19. Bachman DM, Rodrigues MM, Chu FC, Straus SE, Cogan DG, Macher AM. Culture-proven cytomegalovirus retinitis in a homosexual man with the acquired immunodeficiency syndrome. Ophthalmology 1982;89:797-804
20. Neuwirth J, Gutman I, Hofeldt AJ, et al. Cytomegalovirus retinitis in a young homosexual male with acquired immunodeficiency. Ophthalmology 1982;89:805-8
21. Quinnan GV Jr, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 1984;252:72-7
22. Masur H, Michelis MA, Wormser GP, et al. Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med 1982;97:533-9
23. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG. AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science 1986;232:1123-7
24. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-7
25. Shearer GM, Bernstein DC, Tung KS, et al. A model for the selective loss of major histocompatibility complex self-restricted T-cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986;137:2514-21
26. Boyko WJ, Schlechter MT, Craib KJ, et al. The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls. Can Med Assoc J 1986;135:881-7
27. Hague RA, Eden OB, Yap PL, Mok JY, Rae P. Hyperviscosity in HIV infected children-a potential hazard during intravenous immunoglobulin therapy. Blut 1990;61:66-7
28. Martin CM, Matlow AG, Chew E, Sutton D, Pruzanski W. Hyperviscosity syndrome in a patient with acquired immunodeficiency syndrome. Arch Intern Med 1989;149:1435-6
29. Bernard C, Exquis B, Reber G, de Moerloose P. Determination of anti-cardiolipin and other antibodies in HIV-1-infected patients. J Acquir Immune Defic Syndr 1990;3:536-9
30. Chretien P, Monier JC, Oksman F, et al. Autoantibodies and human immunodeficiency viruses infection: a case-control study. Clin Exp Rheumatol 2003;21:210-12
31. Keren DF. Antinuclear antibody testing. Clin Lab Med 2002;22:447-74
32. Savige JA, Chang L, Horn S, Crowe SM. Anti-nuclear, anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies in HIV-infected individuals. Autoimmunity 1994;18:205-11
33. Comely OA, Hauschild S, Weise C, et al. Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection. Infection 1999;27:92-6
34. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669-73
35. Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987;316:1062-8
36. Molina JM, Belenfant X, Doco-Lecompte T, Idatte JM, Modai J. Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis. AIDS 1991;5:587-9
37. Williams DI, Williams DJ, Williams IG, Unwin RJ, Griffiths MH, Miller RF. Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/ AIDS. Sex Transm Infect 1998;74:179-84
38. Herman ES, Klotman PE. HIV-associated nephropathy: Epidemiology, pathogenesis, and treatment. Semin Nephrol 2003;23:200-8
39. Parkin JM, Helbert M, Hughes CL, Pinching AJ. Immunoglobulin G subclass deficiency and susceptibility to pyogenic infections in patients with AIDS-related complex and AIDS. AIDS 1989;3:37-9
40. Lumsden JM, Williams JA, Hodes RJ. Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo. J Immunol 2003;170:781-7
41. Pahwa S. Immune defects in pediatric AIDS, their pathogenesis, and role of immunotherapy. Crit Care Med 1990;18(2 Suppl):S138-43
42. Pahwa R, Good RA, Pahwa S. Prematurity, hypogamma-globulinemia, and neuropathology with human immunodeficiency virus (HIV) infection. Proc Natl Acad Sci USA 1987;84:3826-30
43. Saulsbury FT, Wykoff RF, Boyle RJ. Transfusion-acquired human immunodeficiency virus infection in twelve neonates: epidemiologic, clinical and immunologic features. Pediatr Infect Dis J 1987;6:544-9
44. Whitney CG, Parley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46
45. Jain A, Jain S, Gant V. Should patients positive for HIV infection receive pneumococcal vaccine? BMJ 1995;310:1060
46. Pinching AJ. Antibody responses in HIV infection. Clin Exp Immunol 1991;84:181-4
47. Pierce AB, Hoy JF. Is the recommendation for pneumococcal vaccination of HIV patients evidence based? J Clin Virol 2001;22:255-61
48. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000;19:886-94
49. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T-cells. Nature 1987;326:711-13
50. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-8
51. Lynn WS, Tweedale A, Cloyd MW. Human immunodeficiency virus (HTV-1) cytotoxicity: perturbation of the cell membrane and depression of phospholipid synthesis. Virology 1988;163:43-51
52. Kousignian I, Autran B, Chouquet C, et al. Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients. Stat Med 2003;22:1675-90
53. Rosen FS. The acquired immunodeficiency syndrome (AIDS). J Clin Invest 1985;75:1-3
54. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 1997;278:1447-50
55. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T-cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-25
56. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188(12):2199-204
57. Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 10(6)/ I, AIDS, and death from AIDS? BMJ 1994;309:1535-7
58. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-I infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7
59. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193:169-80
60. Walensky RP, Goldie SJ, Sax PE, et al. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr 2002;31:27-37
61. Easterbrook PJ, Schrager LK. Long-term nonprogression in HIV infection: methodological issues and scientific priorities. Report of an international European community-National Institutes of Health Workshop, The Royal Society, London, England, November 27-29, 1995. Scientific Coordinating Committee. AIDS Res Hum Retroviruses 1998;14:1211-28
62. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-I infection without immunologic progression. AIDS 1994;8:1123-8
63. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993;7:1159-66
64. Easterbrook PJ. Non-progression in HIV infection. AIDS 1994;8:1179-82
65. Catucci M, Venturi G, Romano L, Valensin PE, Zazzi M. Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. J Med Virol 2000;60:294-9
66. Saksena NK, Ge YC, Wang B, et al. An HIV-1 infected long-term non-progressor (LTNP): molecular analysis of HIV-I strains in the vpr and nef genes. Ann Acad Med Singapore 1996;25:848-54
67. Visco-Comandini U, Yun Z, Paganelli R, et al. HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study. J Hum Virol 1998;1:320-7
68. Jekle A, Schramm B, Jayakumar P, et al. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol 2002;76:6966-73
69. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999;5:997-1003
70. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003;424:213-19
71. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8
72. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T-cell responses is associated with non-progression in HIV-1 infection. J Immunol 2002;169:6376-85
73. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002;76:9011-23
74. Marmor M, Sheppard HW, Donnell D, et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-81
75. Altfeld M, Allen TM, Yu XG, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002;420:434-9
76. Ramos A, Hu DJ, Nguyen L, et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol 2002;76:7444-52
77. Koelsch KK, Smith DM, Little SJ, et al. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003;17:F11-16
78. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-9
79. Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science 1996;272:67-74
80. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-52
81. Tang J, Costello C, Keet IP, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999;15:317-24
82. Gao X, Nelson GW, Karacki P, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001;344:1668-75
83. Hendel H, Caillat-Zucman S, Lebuanec H, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999;162:6942-6
84. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502-14
85. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32
86. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001;2:276-313
87. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669-76
88. Su L, Kaneshima H, Bonyhadi M, et al. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity 1995;2:25-36
89. Bonyhadi ML, Rabin L, Salimi S, et al. HIV induces thymus depletion in vivo. Nature 1993;363:728-32
90. Fujimoto S, Yamagishi H. Isolation of an excision product of T-cell receptor alpha-chain gene rearrangements. Nature 1987;327:242-3
91. Okazaki K, Davis DD, Sakano H. T-cell receptor beta gene sequences in the circular DNA of thymocyte nuclei: direct evidence for intramolecular DNA deletion in V-D-J joining. Cell 1987;49:477-85
92. Miedema F. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic Rev 1992;3:173-93
93. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:11-23
94. McMahon DK, Armstrong JA, Huang XL, et al. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 1994;8:59-66
95. Levy Y, Capitant C, Houhou S, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 1999;353:1923-9
96. Levy Y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003;17:343-51
97. Hertoghe T, Wajja A, Ntambi L, et al. T-cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 2000;122:350-7
98. Riddell LA, Pinching AJ, Hill S, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses 2001;17:789-97
99. Murphy PM, Lane HC, Gallin JI, Fauci AS. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med 1988;108:36-41
100. Sun Y, Pinchuk LM, Agy MB, Clark EA. Nuclear import of HPV-1 DNA in resting CD4+ T-cells requires a cyclosporin A-sensitive pathway. J Immunol 1997;158:512-17
101. Minder D, Boni J, Schupbach J, Gehring H. Immunophilins and HIV-1 infection. Arch Virol 2002;147:1531-42
102. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002;29:356-62
103. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002;109:681-8
104. Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003;53:57-64
105. Vigano A, Principi N, Crupi L, Onorato J, Vincenzo ZG, Salvaggio A. Elevation of IgE in HIV-infected children and its correlation with the progression of disease. J Allergy Clin Immunol 1995;95:627-32
106. Parkin JM, Eales LJ, Galazka AR, Pinching AJ. Atopic manifestations in the acquired immune deficiency syndrome: response to recombinant interferon gamma. BMJ (Clin Res Ed) 1987;294:1185-6
107. Marshall GD Jr. AIDS, HIV-positive patients, and allergies. Allergy Asthma Proc 1999;20:301-4
108. Carr A, Cooper DA. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev 1996:65-97
109. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85
110. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-4
111. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30
112. Carr A, Vasak E, Munro V, Penny R, Cooper DA. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994;97:260-5
113. Yoshizawa S, Yasuoka A, Kikuchi Y, et al. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma Immunol 2000;85:241-4
114. Compels MM, Simpson N, Snow M, Spickett G, Ong E. Desensitization to co-trimoxazole (trimethoprim-sulpha-methoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Infect 1999;38:111-15
115. Arrizabalaga J, Casas A, Camino X, Iribarren JA, Rodriguez AF, Von Wichmann MA. [The usefulness of the desensitization to rifampin in the treatment of mycobacterial disease in patients with AIDS]. Med Clin (Barc) 1998;111:103-4